Oncogenic activation of AR during the development and progression of PCa, particularly in the early to late stages of CRPC, is largely dependent on multiple factors including increased protein stability, post‐translational modifications, interactions with specific co‐regulators, and ligand specificity. This evidence concerns the gene AR and posterior cortical atrophy.